Industry Research Reports

Part 1

Part 2

Part 3

Part 4

Part 5

Home > Reports > Medical Care > Global Kidney Fibrosis Treatment Industry Research Report, Growth Trends and Competitive Analysis 2023-2029

Global Kidney Fibrosis Treatment Industry Research Report, Growth Trends and Competitive Analysis 2023-2029

Industry: Medical Care

Published: 2023-05-30

Pages: 102 Pages

Report ld: 658585

Request Sample

Pre-Order Enquiry

Description
Table of Contents
Table of Figures
Related Reports
PDF Download

Description
Table of Contents
Table of Figures
Related Reports
PDF Download

Description

Kidney or renal fibrosis is the body process from which the kidney’s excess fibrous connective tissue or organs takes its formation repetitively.

Due to the COVID-19 pandemic, the global Kidney Fibrosis Treatment market size was US$ million in 2022 and is forecast to a readjusted size of US$ million by 2029 with a CAGR of % during the forecast period 2023-2029. Fully considering the economic change by this health crisis, Angiotensin Converting Enzyme (ACE) Inhibitors accounting for % of the Kidney Fibrosis Treatment global market in 2022, is projected to value US$ million by 2029, growing at a revised % CAGR from 2023 to 2029. While Chronic Kidney Diseases segment is altered to an % CAGR throughout this forecast period.

Increasing prevalence of chronic diseases such as kidney disorders is expected to trigger the growth of this market over the forecast period. Changing life style coupled with changing food habits is the prime reason for rising base of kidney disease patients and is expected to boost the market for kidney fibrosis treatments. Furthermore, factors such as increasing global geriatric population base, rising disposable income of the patients and growing awareness about renal fibrosis treatment are vital  factor for growth of this market during the forecast period. Continuous innovation in technology has led to development of safe and effective therapies for the treatment of chronic kidney diseases is also pushing the growth of kidney fibrosis treatment market. 
The market research report offered here is a very useful resource that can help manufacturers, stakeholders, decision-makers, and other market participants to become familiar with every factor impacting the growth of the global Kidney Fibrosis Treatment market. The analysts authoring the report have closely studied key strategies adopted by top players of the global Kidney Fibrosis Treatment market. The report includes SWOT, and other market analyses to provide a clear and deep understanding of important aspects of the global Kidney Fibrosis Treatment market. Readers of the report can become informed about current and future trends of the global Kidney Fibrosis Treatment market and how they will impact market growth during the forecast period.

Report Metric
Details
Report Title
Global Kidney Fibrosis Treatment Industry Research Report, Growth Trends and Competitive Analysis 2023-2029
Market Size Available for Years
2023-2029
Global Kidney Fibrosis Treatment Companies Covered
Merck and Co(US)
Pfizer Inc(US)
F. Hoffman-La Roche(Switzerland)
InterMune Inc(US)
Galectin Therapeutics(US)
La Jolla Pharmaceutical Company(US)
ProMetic Life-Sciences Inc(Canada)
BioLine Rx(Israel)
Genzyme Corporation(US)
Global Kidney Fibrosis Treatment Market, by Region
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Forecast Units
USD million in value
Report Coverage
Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc.), including the market size of each market segment, future development potential, and so on.
Chapter 2: Revenue of Kidney Fibrosis Treatment in global and regional level.
Chapter 3: Detailed analysis of Kidney Fibrosis Treatment companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America (US & Canada) by type, by application and by country, revenue for each segment.
Chapter 7: Europe by type, by application and by country, revenue for each segment.
Chapter 8: Asia Pacific by type, by application and by region, revenue for each segment.
Chapter 9: Latin America by type, by application and by country, revenue for each segment.
Chapter 10: Middle East and Africa, by type, by application and by country, revenue for each segment.
Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Kidney Fibrosis Treatment revenue, gross margin, and recent development, etc.
Chapter 12: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 13: Research Findings and Conclusion

Table of Contents

1 Report Overview
    1.1 Study Scope
    1.2 Market Analysis by Type
        1.2.1 Global Kidney Fibrosis Treatment Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
        1.2.2 Angiotensin Converting Enzyme (ACE) Inhibitors
        1.2.3 Pirfenidone
        1.2.4 Renin Inhibitors
        1.2.5 Angiotensin II Receptor Blockers (ARBs)
        1.2.6 Vasopeptidase Inhibitors
    1.3 Market by Application
        1.3.1 Global Kidney Fibrosis Treatment Market Growth Rate by Application: 2018 VS 2022 VS 2029
        1.3.2 Chronic Kidney Diseases
        1.3.3 Kidney Cancer Treatment
        1.3.4 Others
    1.4 Assumptions and Limitations
    1.5 Study Objectives
    1.6 Years Considered

2 Market Perspective
    2.1 Global Kidney Fibrosis Treatment Market Size (2018-2029)
    2.2 Kidney Fibrosis Treatment Market Size across Key Geographies Worldwide: 2018 VS 2022 VS 2029
    2.3 Global Kidney Fibrosis Treatment Market Size by Region (2018-2023)
    2.4 Global Kidney Fibrosis Treatment Market Size Forecast by Region (2024-2029)
    2.5 Global Top 10 Kidney Fibrosis Treatment Countries Ranking by Market Size

3 Kidney Fibrosis Treatment Competitive by Company
    3.1 Global Kidney Fibrosis Treatment Revenue by Players
        3.1.1 Global Kidney Fibrosis Treatment Revenue by Players (2018-2023)
        3.1.2 Global Kidney Fibrosis Treatment Market Share by Players (2018-2023)
    3.2 Global Kidney Fibrosis Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
    3.3 Company Covered: Ranking by Kidney Fibrosis Treatment Revenue
    3.4 Global Kidney Fibrosis Treatment Market Concentration Ratio
        3.4.1 Global Kidney Fibrosis Treatment Market Concentration Ratio (CR5 and HHI)
        3.4.2 Global Top 10 and Top 5 Companies by Kidney Fibrosis Treatment Revenue in 2022
    3.5 Global Key Players of Kidney Fibrosis Treatment Head office and Area Served
    3.6 Global Key Players of Kidney Fibrosis Treatment, Product and Application
    3.7 Global Key Players of Kidney Fibrosis Treatment, Date of Enter into This Industry
    3.8 Mergers & Acquisitions, Expansion Plans

4 Global Kidney Fibrosis Treatment Breakdown Data by Type
    4.1 Global Kidney Fibrosis Treatment Historic Revenue by Type (2018-2023)
    4.2 Global Kidney Fibrosis Treatment Forecasted Revenue by Type (2024-2029)

5 Global Kidney Fibrosis Treatment Breakdown Data by Application
    5.1 Global Kidney Fibrosis Treatment Historic Market Size by Application (2018-2023)
    5.2 Global Kidney Fibrosis Treatment Forecasted Market Size by Application (2024-2029)

6 North America
    6.1 North America Kidney Fibrosis Treatment Revenue by Company (2021-2023)
    6.2 North America Kidney Fibrosis Treatment Revenue by Type (2018-2029)
    6.3 North America Kidney Fibrosis Treatment Revenue by Application (2018-2029)
    6.4 North America Kidney Fibrosis Treatment Revenue by Country (2018-2029)
        6.4.1 U.S.
        6.4.2 Canada

7 Europe
    7.1 Europe Kidney Fibrosis Treatment Revenue by Company (2021-2023)
    7.2 Europe Kidney Fibrosis Treatment Revenue by Type (2018-2029)
    7.3 Europe Kidney Fibrosis Treatment Revenue by Application (2018-2029)
    7.4 Europe Kidney Fibrosis Treatment Revenue by Country (2018-2029)
        7.4.1 Germany
        7.4.2 France
        7.4.3 U.K.
        7.4.4 Italy
        7.4.5 Russia

8 Asia Pacific
    8.1 Asia Pacific Kidney Fibrosis Treatment Revenue by Company (2021-2023)
    8.2 Asia Pacific Kidney Fibrosis Treatment Revenue by Type (2018-2029)
    8.3 Asia Pacific Kidney Fibrosis Treatment Revenue by Application (2018-2029)
    8.4 Asia Pacific Kidney Fibrosis Treatment Revenue by Region (2018-2029)
        8.4.1 China
        8.4.2 Japan
        8.4.3 South Korea
        8.4.4 India
        8.4.5 Australia
        8.4.6 Taiwan
        8.4.7 Indonesia
        8.4.8 Thailand
        8.4.9 Malaysia
        8.4.10 Philippines
        8.4.11 Vietnam

9 Latin America
    9.1 Latin America Kidney Fibrosis Treatment Revenue by Company (2021-2023)
    9.2 Latin America Kidney Fibrosis Treatment Revenue by Type (2018-2029)
    9.3 Latin America Kidney Fibrosis Treatment Revenue by Application (2018-2029)
    9.4 Latin America Kidney Fibrosis Treatment Revenue by Country (2018-2029)
        9.4.1 Mexico
        9.4.2 Brazil
        9.4.3 Argentina

10 Middle East and Africa
    10.1 Middle East and Africa Kidney Fibrosis Treatment Revenue by Company (2021-2023)
    10.2 Middle East and Africa Kidney Fibrosis Treatment Revenue by Type (2018-2029)
    10.3 Middle East and Africa Kidney Fibrosis Treatment Revenue by Application (2018-2029)
    10.4 Middle East and Africa Kidney Fibrosis Treatment Revenue by Country (2018-2029)
        10.4.1 Turkey
        10.4.2 Saudi Arabia
        10.4.3 UAE

11 Company Profiles
    11.1 Merck and Co(US)
        11.1.1 Merck and Co(US) Company Details
        11.1.2 Merck and Co(US) Business Overview
        11.1.3 Merck and Co(US) Kidney Fibrosis Treatment Products and Services
        11.1.4 Merck and Co(US) Kidney Fibrosis Treatment Revenue in Kidney Fibrosis Treatment Business (2018-2023)
        11.1.5 Merck and Co(US) Kidney Fibrosis Treatment SWOT Analysis
        11.1.6 Merck and Co(US) Recent Development
    11.2 Pfizer Inc(US)
        11.2.1 Pfizer Inc(US) Company Details
        11.2.2 Pfizer Inc(US) Business Overview
        11.2.3 Pfizer Inc(US) Kidney Fibrosis Treatment Products and Services
        11.2.4 Pfizer Inc(US) Kidney Fibrosis Treatment Revenue in Kidney Fibrosis Treatment Business (2018-2023)
        11.2.5 Pfizer Inc(US) Kidney Fibrosis Treatment SWOT Analysis
        11.2.6 Pfizer Inc(US) Recent Development
    11.3 F. Hoffman-La Roche(Switzerland)
        11.3.1 F. Hoffman-La Roche(Switzerland) Company Details
        11.3.2 F. Hoffman-La Roche(Switzerland) Business Overview
        11.3.3 F. Hoffman-La Roche(Switzerland) Kidney Fibrosis Treatment Products and Services
        11.3.4 F. Hoffman-La Roche(Switzerland) Kidney Fibrosis Treatment Revenue in Kidney Fibrosis Treatment Business (2018-2023)
        11.3.5 F. Hoffman-La Roche(Switzerland) Kidney Fibrosis Treatment SWOT Analysis
        11.3.6 F. Hoffman-La Roche(Switzerland) Recent Development
    11.4 InterMune Inc(US)
        11.4.1 InterMune Inc(US) Company Details
        11.4.2 InterMune Inc(US) Business Overview
        11.4.3 InterMune Inc(US) Kidney Fibrosis Treatment Products and Services
        11.4.4 InterMune Inc(US) Kidney Fibrosis Treatment Revenue in Kidney Fibrosis Treatment Business (2018-2023)
        11.4.5 InterMune Inc(US) Kidney Fibrosis Treatment SWOT Analysis
        11.4.6 InterMune Inc(US) Recent Development
    11.5 Galectin Therapeutics(US)
        11.5.1 Galectin Therapeutics(US) Company Details
        11.5.2 Galectin Therapeutics(US) Business Overview
        11.5.3 Galectin Therapeutics(US) Kidney Fibrosis Treatment Products and Services
        11.5.4 Galectin Therapeutics(US) Kidney Fibrosis Treatment Revenue in Kidney Fibrosis Treatment Business (2018-2023)
        11.5.5 Galectin Therapeutics(US) Kidney Fibrosis Treatment SWOT Analysis
        11.5.6 Galectin Therapeutics(US) Recent Development
    11.6 La Jolla Pharmaceutical Company(US)
        11.6.1 La Jolla Pharmaceutical Company(US) Company Details
        11.6.2 La Jolla Pharmaceutical Company(US) Business Overview
        11.6.3 La Jolla Pharmaceutical Company(US) Kidney Fibrosis Treatment Products and Services
        11.6.4 La Jolla Pharmaceutical Company(US) Kidney Fibrosis Treatment Revenue in Kidney Fibrosis Treatment Business (2018-2023)
        11.6.5 La Jolla Pharmaceutical Company(US) Kidney Fibrosis Treatment SWOT Analysis
        11.6.6 La Jolla Pharmaceutical Company(US) Recent Development
    11.7 ProMetic Life-Sciences Inc(Canada)
        11.7.1 ProMetic Life-Sciences Inc(Canada) Company Details
        11.7.2 ProMetic Life-Sciences Inc(Canada) Business Overview
        11.7.3 ProMetic Life-Sciences Inc(Canada) Kidney Fibrosis Treatment Products and Services
        11.7.4 ProMetic Life-Sciences Inc(Canada) Kidney Fibrosis Treatment Revenue in Kidney Fibrosis Treatment Business (2018-2023)
        11.7.5 ProMetic Life-Sciences Inc(Canada) Kidney Fibrosis Treatment SWOT Analysis
        11.7.6 ProMetic Life-Sciences Inc(Canada) Recent Development
    11.8 BioLine Rx(Israel)
        11.8.1 BioLine Rx(Israel) Company Details
        11.8.2 BioLine Rx(Israel) Business Overview
        11.8.3 BioLine Rx(Israel) Kidney Fibrosis Treatment Products and Services
        11.8.4 BioLine Rx(Israel) Kidney Fibrosis Treatment Revenue in Kidney Fibrosis Treatment Business (2018-2023)
        11.8.5 BioLine Rx(Israel) Kidney Fibrosis Treatment SWOT Analysis
        11.8.6 BioLine Rx(Israel) Recent Development
    11.9 Genzyme Corporation(US)
        11.9.1 Genzyme Corporation(US) Company Details
        11.9.2 Genzyme Corporation(US) Business Overview
        11.9.3 Genzyme Corporation(US) Kidney Fibrosis Treatment Products and Services
        11.9.4 Genzyme Corporation(US) Kidney Fibrosis Treatment Revenue in Kidney Fibrosis Treatment Business (2018-2023)
        11.9.5 Genzyme Corporation(US) Kidney Fibrosis Treatment SWOT Analysis
        11.9.6 Genzyme Corporation(US) Recent Development

12 Kidney Fibrosis Treatment Market Dynamics
    12.1 Kidney Fibrosis Treatment Industry Trends
    12.2 Kidney Fibrosis Treatment Market Drivers
    12.3 Kidney Fibrosis Treatment Market Challenges
    12.4 Kidney Fibrosis Treatment Market Restraints

13 Research Findings and Conclusion

14 Appendix
    14.1 Research Methodology
        14.1.1 Methodology/Research Approach
        14.1.2 Data Source
    14.2 Author Details

Table of Figures

List of Tables
    Table 1. Global Kidney Fibrosis Treatment Market Size Growth Rate (CAGR) by Type (US$ Million), 2018 VS 2022 VS 2029
    Table 2. Key Players of Angiotensin Converting Enzyme (ACE) Inhibitors
    Table 3. Key Players of Pirfenidone
    Table 4. Key Players of Renin Inhibitors
    Table 5. Key Players of Angiotensin II Receptor Blockers (ARBs)
    Table 6. Key Players of Vasopeptidase Inhibitors
    Table 7. Global Kidney Fibrosis Treatment Market Size Growth Rate by Application (US$ Million), 2018 VS 2022 VS 2029
    Table 8. Global Kidney Fibrosis Treatment Market Size (US$ Million) Growth Rate (CAGR) by Region: 2018 VS 2022 VS 2029
    Table 9. Global Kidney Fibrosis Treatment Revenue by Region (2018-2023) & (US$ Million)
    Table 10. Global Kidney Fibrosis Treatment Revenue Forecast by Region (2024-2029) & (US$ Million)
    Table 11. Global Kidney Fibrosis Treatment Market Size of Top 10 Countries, 2018 VS 2022 VS 2029, (US$ Million)
    Table 12. Global Kidney Fibrosis Treatment Revenue by Players (2018-2023) & (US$ Million)
    Table 13. Global Kidney Fibrosis Treatment Market Share by Players (2018-2023)
    Table 14. Global Top Kidney Fibrosis Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Kidney Fibrosis Treatment as of 2022)
    Table 15. Ranking of Global Top Kidney Fibrosis Treatment Companies by Revenue (US$ Million) in 2022
    Table 16. Global 5 Largest Players Market Share by Kidney Fibrosis Treatment Revenue (CR5 and HHI) & (2018-2023)
    Table 17. Global Key Players of Kidney Fibrosis Treatment, Headquarters and Area Served
    Table 18. Global Key Players of Kidney Fibrosis Treatment, Product and Application
    Table 19. Global Key Players of Kidney Fibrosis Treatment, Date of Enter into This Industry
    Table 20. Mergers & Acquisitions, Expansion Plans
    Table 21. Global Kidney Fibrosis Treatment Market Size by Type (2018-2023) & (US$ Million)
    Table 22. Global Kidney Fibrosis Treatment Revenue Market Share by Type (2018-2023)
    Table 23. Global Kidney Fibrosis Treatment Forecasted Market Size by Type (2024-2029) & (US$ Million)
    Table 24. Global Kidney Fibrosis Treatment Revenue Market Share by Type (2024-2029)
    Table 25. Global Kidney Fibrosis Treatment Market Size by Application (2018-2023) & (US$ Million)
    Table 26. Global Kidney Fibrosis Treatment Revenue Market Share by Application (2018-2023)
    Table 27. Global Kidney Fibrosis Treatment Forecasted Market Size by Application (2024-2029) & (US$ Million)
    Table 28. Global Kidney Fibrosis Treatment Revenue Market Share by Application (2024-2029)
    Table 29. North America Kidney Fibrosis Treatment Revenue by Company (2021-2023) & (US$ Million)
    Table 30. North America Kidney Fibrosis Treatment Revenue by Type (2018-2023) & (US$ Million)
    Table 31. North America Kidney Fibrosis Treatment Revenue by Type (2024-2029) & (US$ Million)
    Table 32. North America Kidney Fibrosis Treatment Revenue by Application (2018-2023) & (US$ Million)
    Table 33. North America Kidney Fibrosis Treatment Revenue by Application (2024-2029) & (US$ Million)
    Table 34. North America Kidney Fibrosis Treatment Revenue Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2029
    Table 35. North America Kidney Fibrosis Treatment Revenue by Country (2018-2023) & (US$ Million)
    Table 36. North America Kidney Fibrosis Treatment Revenue by Country (2024-2029) & (US$ Million)
    Table 37. Europe Kidney Fibrosis Treatment Revenue by Company (2021-2023) & (US$ Million)
    Table 38. Europe Kidney Fibrosis Treatment Revenue by Type (2018-2023) & (US$ Million)
    Table 39. Europe Kidney Fibrosis Treatment Revenue by Type (2024-2029) & (US$ Million)
    Table 40. Europe Kidney Fibrosis Treatment Revenue by Application (2018-2023) & (US$ Million)
    Table 41. Europe Kidney Fibrosis Treatment Revenue by Application (2024-2029) & (US$ Million)
    Table 42. Europe Kidney Fibrosis Treatment Revenue Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2029
    Table 43. Europe Kidney Fibrosis Treatment Revenue by Country (2018-2023) & (US$ Million)
    Table 44. Europe Kidney Fibrosis Treatment Revenue by Country (2024-2029) & (US$ Million)
    Table 45. Asia Pacific Kidney Fibrosis Treatment Revenue by Company (2021-2023) & (US$ Million)
    Table 46. Asia Pacific Kidney Fibrosis Treatment Revenue by Type (2018-2023) & (US$ Million)
    Table 47. Asia Pacific Kidney Fibrosis Treatment Revenue by Type (2024-2029) & (US$ Million)
    Table 48. Asia Pacific Kidney Fibrosis Treatment Revenue by Application (2018-2023) & (US$ Million)
    Table 49. Asia Pacific Kidney Fibrosis Treatment Revenue by Application (2024-2029) & (US$ Million)
    Table 50. Asia-Pacific Kidney Fibrosis Treatment Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2029
    Table 51. Asia Pacific Kidney Fibrosis Treatment Revenue by Region (2018-2023) & (US$ Million)
    Table 52. Asia Pacific Kidney Fibrosis Treatment Revenue by Region (2024-2029) & (US$ Million)
    Table 53. Latin America Kidney Fibrosis Treatment Revenue by Company (2021-2023) & (US$ Million)
    Table 54. Latin America Kidney Fibrosis Treatment Revenue by Type (2018-2023) & (US$ Million)
    Table 55. Latin America Kidney Fibrosis Treatment Revenue by Type (2024-2029) & (US$ Million)
    Table 56. Latin America Kidney Fibrosis Treatment Revenue by Application (2018-2023) & (US$ Million)
    Table 57. Latin America Kidney Fibrosis Treatment Revenue by Application (2024-2029) & (US$ Million)
    Table 58. Latin America Kidney Fibrosis Treatment Revenue Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2029
    Table 59. Latin America Kidney Fibrosis Treatment Revenue by Country (2018-2023) & (US$ Million)
    Table 60. Latin America Kidney Fibrosis Treatment Revenue by Country (2024-2029) & (US$ Million)
    Table 61. Middle East and Africa Kidney Fibrosis Treatment Revenue by Company (2021-2023) & (US$ Million)
    Table 62. Middle East and Africa Kidney Fibrosis Treatment Revenue by Type (2018-2023) & (US$ Million)
    Table 63. Middle East and Africa Kidney Fibrosis Treatment Revenue by Type (2024-2029) & (US$ Million)
    Table 64. Middle East and Africa Kidney Fibrosis Treatment Revenue by Application (2018-2023) & (US$ Million)
    Table 65. Middle East and Africa Kidney Fibrosis Treatment Revenue by Application (2024-2029) & (US$ Million)
    Table 66. Middle East and Africa Kidney Fibrosis Treatment Revenue Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2029
    Table 67. Middle East and Africa Kidney Fibrosis Treatment Revenue by Country (2018-2023) & (US$ Million)
    Table 68. Middle East and Africa Kidney Fibrosis Treatment Revenue by Country (2024-2029) & (US$ Million)
    Table 69. Merck and Co(US) Company Details
    Table 70. Merck and Co(US) Business Overview
    Table 71. Merck and Co(US) Kidney Fibrosis Treatment Product and Services
    Table 72. Merck and Co(US) Kidney Fibrosis Treatment Revenue in Kidney Fibrosis Treatment Business (2018-2023) & (US$ Million)
    Table 73. Merck and Co(US) Kidney Fibrosis Treatment SWOT Analysis
    Table 74. Merck and Co(US) Recent Development
    Table 75. Pfizer Inc(US) Company Details
    Table 76. Pfizer Inc(US) Business Overview
    Table 77. Pfizer Inc(US) Kidney Fibrosis Treatment Product and Services
    Table 78. Pfizer Inc(US) Kidney Fibrosis Treatment Revenue in Kidney Fibrosis Treatment Business (2018-2023) & (US$ Million)
    Table 79. Pfizer Inc(US) Kidney Fibrosis Treatment SWOT Analysis
    Table 80. Pfizer Inc(US) Recent Development
    Table 81. F. Hoffman-La Roche(Switzerland) Company Details
    Table 82. F. Hoffman-La Roche(Switzerland) Business Overview
    Table 83. F. Hoffman-La Roche(Switzerland) Kidney Fibrosis Treatment Product and Services
    Table 84. F. Hoffman-La Roche(Switzerland) Kidney Fibrosis Treatment Revenue in Kidney Fibrosis Treatment Business (2018-2023) & (US$ Million)
    Table 85. F. Hoffman-La Roche(Switzerland) Kidney Fibrosis Treatment SWOT Analysis
    Table 86. F. Hoffman-La Roche(Switzerland) Recent Development
    Table 87. InterMune Inc(US) Company Details
    Table 88. InterMune Inc(US) Business Overview
    Table 89. InterMune Inc(US) Kidney Fibrosis Treatment Product and Services
    Table 90. InterMune Inc(US) Kidney Fibrosis Treatment Revenue in Kidney Fibrosis Treatment Business (2018-2023) & (US$ Million)
    Table 91. InterMune Inc(US) Kidney Fibrosis Treatment SWOT Analysis
    Table 92. InterMune Inc(US) Recent Development
    Table 93. Galectin Therapeutics(US) Company Details
    Table 94. Galectin Therapeutics(US) Business Overview
    Table 95. Galectin Therapeutics(US) Kidney Fibrosis Treatment Product and Services
    Table 96. Galectin Therapeutics(US) Kidney Fibrosis Treatment Revenue in Kidney Fibrosis Treatment Business (2018-2023) & (US$ Million)
    Table 97. Galectin Therapeutics(US) Kidney Fibrosis Treatment SWOT Analysis
    Table 98. Galectin Therapeutics(US) Recent Development
    Table 99. La Jolla Pharmaceutical Company(US) Company Details
    Table 100. La Jolla Pharmaceutical Company(US) Business Overview
    Table 101. La Jolla Pharmaceutical Company(US) Kidney Fibrosis Treatment Product and Services
    Table 102. La Jolla Pharmaceutical Company(US) Kidney Fibrosis Treatment Revenue in Kidney Fibrosis Treatment Business (2018-2023) & (US$ Million)
    Table 103. La Jolla Pharmaceutical Company(US) Kidney Fibrosis Treatment SWOT Analysis
    Table 104. La Jolla Pharmaceutical Company(US) Recent Development
    Table 105. ProMetic Life-Sciences Inc(Canada) Company Details
    Table 106. ProMetic Life-Sciences Inc(Canada) Business Overview
    Table 107. ProMetic Life-Sciences Inc(Canada) Kidney Fibrosis Treatment Product and Services
    Table 108. ProMetic Life-Sciences Inc(Canada) Kidney Fibrosis Treatment Revenue in Kidney Fibrosis Treatment Business (2018-2023) & (US$ Million)
    Table 109. ProMetic Life-Sciences Inc(Canada) Kidney Fibrosis Treatment SWOT Analysis
    Table 110. ProMetic Life-Sciences Inc(Canada) Recent Development
    Table 111. BioLine Rx(Israel) Company Details
    Table 112. BioLine Rx(Israel) Business Overview
    Table 113. BioLine Rx(Israel) Kidney Fibrosis Treatment Product and Services
    Table 114. BioLine Rx(Israel) Kidney Fibrosis Treatment Revenue in Kidney Fibrosis Treatment Business (2018-2023) & (US$ Million)
    Table 115. BioLine Rx(Israel) Kidney Fibrosis Treatment SWOT Analysis
    Table 116. BioLine Rx(Israel) Recent Development
    Table 117. Genzyme Corporation(US) Company Details
    Table 118. Genzyme Corporation(US) Business Overview
    Table 119. Genzyme Corporation(US) Kidney Fibrosis Treatment Product and Services
    Table 120. Genzyme Corporation(US) Kidney Fibrosis Treatment Revenue in Kidney Fibrosis Treatment Business (2018-2023) & (US$ Million)
    Table 121. Genzyme Corporation(US) Kidney Fibrosis Treatment SWOT Analysis
    Table 122. Genzyme Corporation(US) Recent Development
    Table 123. Kidney Fibrosis Treatment Market Trends
    Table 124. Kidney Fibrosis Treatment Market Drivers
    Table 125. Kidney Fibrosis Treatment Market Challenges
    Table 126. Kidney Fibrosis Treatment Market Restraints
    Table 127. Research Programs/Design for This Report
    Table 128. Key Data Information from Secondary Sources
    Table 129. Key Data Information from Primary Sources
List of Figures
    Figure 1. Kidney Fibrosis Treatment Product Picture
    Figure 2. Global Kidney Fibrosis Treatment Market Size by Type (US$ Million): 2018 VS 2022 VS 2029
    Figure 3. Global Kidney Fibrosis Treatment Market Share by Type: 2022 VS 2029
    Figure 4. Angiotensin Converting Enzyme (ACE) Inhibitors Features
    Figure 5. Pirfenidone Features
    Figure 6. Renin Inhibitors Features
    Figure 7. Angiotensin II Receptor Blockers (ARBs) Features
    Figure 8. Vasopeptidase Inhibitors Features
    Figure 9. Global Kidney Fibrosis Treatment Market Size by Application (US$ Million): 2018 VS 2022 VS 2029
    Figure 10. Global Kidney Fibrosis Treatment Market Share by Application: 2022 VS 2029
    Figure 11. Chronic Kidney Diseases
    Figure 12. Kidney Cancer Treatment
    Figure 13. Others
    Figure 14. Kidney Fibrosis Treatment Report Years Considered
    Figure 15. Global Kidney Fibrosis Treatment Revenue, (US$ Million), 2018 VS 2022 VS 2029
    Figure 16. Global Kidney Fibrosis Treatment Market Size 2018-2029 (US$ Million)
    Figure 17. Global Kidney Fibrosis Treatment Market Size Market Share by Region: 2022 VS 2029
    Figure 18. Global Kidney Fibrosis Treatment Revenue Market Share by Region in 2018 VS 2022
    Figure 19. Global Kidney Fibrosis Treatment Revenue Market Share Forecast by Region (2024-2029)
    Figure 20. Global Top 10 Kidney Fibrosis Treatment Countries Ranking by Market Size (US$ Million) in 2022
    Figure 21. Global Kidney Fibrosis Treatment Market Size of Top 10 Countries, 2018 VS 2022 VS 2029, (US$ Million)
    Figure 22. Global Kidney Fibrosis Treatment Market Share by Players in 2022
    Figure 23. Global Top Kidney Fibrosis Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Kidney Fibrosis Treatment as of 2022)
    Figure 24. The Top 10 and 5 Players Market Share by Kidney Fibrosis Treatment Revenue in 2022
    Figure 25. North America Kidney Fibrosis Treatment Revenue Market Share by Company in 2022
    Figure 26. North America Kidney Fibrosis Treatment Revenue Market Share by Type (2018-2029)
    Figure 27. North America Kidney Fibrosis Treatment Revenue Market Share by Application (2018-2029)
    Figure 28. North America Kidney Fibrosis Treatment Revenue Share by Country (2018-2029)
    Figure 29. U.S. Kidney Fibrosis Treatment Revenue (2018-2029) & (US$ Million)
    Figure 30. Canada Kidney Fibrosis Treatment Revenue (2018-2029) & (US$ Million)
    Figure 31. Europe Kidney Fibrosis Treatment Revenue Market Share by Company in 2022
    Figure 32. Europe Kidney Fibrosis Treatment Revenue Market Share by Type (2018-2029)
    Figure 33. Europe Kidney Fibrosis Treatment Revenue Market Share by Application (2018-2029)
    Figure 34. Europe Kidney Fibrosis Treatment Revenue Share by Country (2018-2029)
    Figure 35. Germany Kidney Fibrosis Treatment Revenue (2018-2029) & (US$ Million)
    Figure 36. France Kidney Fibrosis Treatment Revenue (2018-2029) & (US$ Million)
    Figure 37. U.K. Kidney Fibrosis Treatment Revenue (2018-2029) & (US$ Million)
    Figure 38. Italy Kidney Fibrosis Treatment Revenue (2018-2029) & (US$ Million)
    Figure 39. Russia Kidney Fibrosis Treatment Revenue (2018-2029) & (US$ Million)
    Figure 40. Asia Pacific Kidney Fibrosis Treatment Revenue Market Share by Company in 2022
    Figure 41. Asia Pacific Kidney Fibrosis Treatment Revenue Market Share by Type (2018-2029)
    Figure 42. Asia Pacific Kidney Fibrosis Treatment Revenue Market Share by Application (2018-2029)
    Figure 43. Asia Pacific Kidney Fibrosis Treatment Revenue Share by Region (2018-2029)
    Figure 44. China Kidney Fibrosis Treatment Revenue (2018-2029) & (US$ Million)
    Figure 45. Japan Kidney Fibrosis Treatment Revenue (2018-2029) & (US$ Million)
    Figure 46. South Korea Kidney Fibrosis Treatment Revenue (2018-2029) & (US$ Million)
    Figure 47. India Kidney Fibrosis Treatment Revenue (2018-2029) & (US$ Million)
    Figure 48. Australia Kidney Fibrosis Treatment Revenue (2018-2029) & (US$ Million)
    Figure 49. Taiwan Kidney Fibrosis Treatment Revenue (2018-2029) & (US$ Million)
    Figure 50. Indonesia Kidney Fibrosis Treatment Revenue (2018-2029) & (US$ Million)
    Figure 51. Thailand Kidney Fibrosis Treatment Revenue (2018-2029) & (US$ Million)
    Figure 52. Malaysia Kidney Fibrosis Treatment Revenue (2018-2029) & (US$ Million)
    Figure 53. Philippines Kidney Fibrosis Treatment Revenue (2018-2029) & (US$ Million)
    Figure 54. Vietnam Kidney Fibrosis Treatment Revenue (2018-2029) & (US$ Million)
    Figure 55. Latin America Kidney Fibrosis Treatment Revenue Market Share by Company in 2022
    Figure 56. Latin America Kidney Fibrosis Treatment Revenue Market Share by Type (2018-2029)
    Figure 57. Latin America Kidney Fibrosis Treatment Revenue Market Share by Application (2018-2029)
    Figure 58. Latin America Kidney Fibrosis Treatment Revenue Share by Country (2018-2029)
    Figure 59. Mexico Kidney Fibrosis Treatment Revenue (2018-2029) & (US$ Million)
    Figure 60. Brazil Kidney Fibrosis Treatment Revenue (2018-2029) & (US$ Million)
    Figure 61. Argentina Kidney Fibrosis Treatment Revenue (2018-2029) & (US$ Million)
    Figure 62. Middle East and Africa Kidney Fibrosis Treatment Revenue Market Share by Company in 2022
    Figure 63. Middle East and Africa Kidney Fibrosis Treatment Revenue Market Share by Type (2018-2029)
    Figure 64. Middle East and Africa Kidney Fibrosis Treatment Revenue Market Share by Application (2018-2029)
    Figure 65. Middle East and Africa Kidney Fibrosis Treatment Revenue Share by Country (2018-2029)
    Figure 66. Turkey Kidney Fibrosis Treatment Revenue (2018-2029) & (US$ Million)
    Figure 67. Saudi Arabia Kidney Fibrosis Treatment Revenue (2018-2029) & (US$ Million)
    Figure 68. UAE Kidney Fibrosis Treatment Revenue (2018-2029) & (US$ Million)
    Figure 69. Merck and Co(US) Revenue Growth Rate in Kidney Fibrosis Treatment Business (2018-2023)
    Figure 70. Pfizer Inc(US) Revenue Growth Rate in Kidney Fibrosis Treatment Business (2018-2023)
    Figure 71. F. Hoffman-La Roche(Switzerland) Revenue Growth Rate in Kidney Fibrosis Treatment Business (2018-2023)
    Figure 72. InterMune Inc(US) Revenue Growth Rate in Kidney Fibrosis Treatment Business (2018-2023)
    Figure 73. Galectin Therapeutics(US) Revenue Growth Rate in Kidney Fibrosis Treatment Business (2018-2023)
    Figure 74. La Jolla Pharmaceutical Company(US) Revenue Growth Rate in Kidney Fibrosis Treatment Business (2018-2023)
    Figure 75. ProMetic Life-Sciences Inc(Canada) Revenue Growth Rate in Kidney Fibrosis Treatment Business (2018-2023)
    Figure 76. BioLine Rx(Israel) Revenue Growth Rate in Kidney Fibrosis Treatment Business (2018-2023)
    Figure 77. Genzyme Corporation(US) Revenue Growth Rate in Kidney Fibrosis Treatment Business (2018-2023)
    Figure 78. Bottom-up and Top-down Approaches for This Report
    Figure 79. Data Triangulation
    Figure 80. Key Executives Interviewed

Description

Kidney or renal fibrosis is the body process from which the kidney’s excess fibrous connective tissue or organs takes its formation repetitively.

Due to the COVID-19 pandemic, the global Kidney Fibrosis Treatment market size was US$ million in 2022 and is forecast to a readjusted size of US$ million by 2029 with a CAGR of % during the forecast period 2023-2029. Fully considering the economic change by this health crisis, Angiotensin Converting Enzyme (ACE) Inhibitors accounting for % of the Kidney Fibrosis Treatment global market in 2022, is projected to value US$ million by 2029, growing at a revised % CAGR from 2023 to 2029. While Chronic Kidney Diseases segment is altered to an % CAGR throughout this forecast period.

Increasing prevalence of chronic diseases such as kidney disorders is expected to trigger the growth of this market over the forecast period. Changing life style coupled with changing food habits is the prime reason for rising base of kidney disease patients and is expected to boost the market for kidney fibrosis treatments. Furthermore, factors such as increasing global geriatric population base, rising disposable income of the patients and growing awareness about renal fibrosis treatment are vital  factor for growth of this market during the forecast period. Continuous innovation in technology has led to development of safe and effective therapies for the treatment of chronic kidney diseases is also pushing the growth of kidney fibrosis treatment market. 
The market research report offered here is a very useful resource that can help manufacturers, stakeholders, decision-makers, and other market participants to become familiar with every factor impacting the growth of the global Kidney Fibrosis Treatment market. The analysts authoring the report have closely studied key strategies adopted by top players of the global Kidney Fibrosis Treatment market. The report includes SWOT, and other market analyses to provide a clear and deep understanding of important aspects of the global Kidney Fibrosis Treatment market. Readers of the report can become informed about current and future trends of the global Kidney Fibrosis Treatment market and how they will impact market growth during the forecast period.

Related Reports

Global Kidney Fibrosis Treatment Market Research Report 2023
Kidney or renal fibrosis is the body process from which the kidney’s excess fibrous connective tissue or organs takes its formation repetitively.
Published: 2023-06-11
Pages: 85
USD 2900.00
(Single User License)
Global Kidney Fibrosis Treatment Market Insights, Forecast to 2029
Kidney or renal fibrosis is the body process from which the kidney’s excess fibrous connective tissue or organs takes its formation repetitively.
Published: 2023-05-31
Pages: 91
USD 4900.00
(Single User License)
Global Kidney Fibrosis Treatment Market Report, History and Forecast 2018-2029, Breakdown Data by Companies, Key Regions, Types and Application
Kidney or renal fibrosis is the body process from which the kidney’s excess fibrous connective tissue or organs takes its formation repetitively.
Published: 2023-05-30
Pages: 88
USD 3350.00
(Single User License)
Global Kidney Fibrosis Treatment Market Research Report 2024
Kidney or renal fibrosis is the body process from which the kidney’s excess fibrous connective tissue or organs takes its formation repetitively.
Published: 2024-01-04
Pages: 78
USD 2900.00
(Single User License)
Kidney Fibrosis Treatment - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Kidney or renal fibrosis is the body process from which the kidney’s excess fibrous connective tissue or organs takes its formation repetitively.
Published: 2024-01-24
Pages: 92
USD 3950.00
(Single User License)
Global Kidney Fibrosis Treatment Market Insights, Forecast to 2030
Kidney or renal fibrosis is the body process from which the kidney’s excess fibrous connective tissue or organs takes its formation repetitively.
Published: 2024-04-28
Pages: 88
USD 4900.00
(Single User License)
Global Kidney Fibrosis Treatment Market Research Report 2025
The global market for Kidney Fibrosis Treatment was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
Published: 2025-02-27
Pages: 71
USD 2900.00
(Single User License)
Kidney Fibrosis Treatment- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Kidney Fibrosis Treatment was estimated to be worth US$ million in 2024 and is forecast to a readjusted size of US$ million by 2031 with a CAGR of %during the forecast period 2025-2031.
Published: 2025-02-27
Pages: 89
USD 3950.00
(Single User License)